Lorlatinib / Lorbrena
Lorlatinib (Lorbrena)
Lorlatinib, marketed under the brand name Lorbrena, is a medication used in the treatment of non-small cell lung cancer (NSCLC). It is particularly effective for patients whose cancer has specific genetic mutations. This note provides an overview of Lorlatinib, including its mechanism of action, indications, administration, side effects, and clinical considerations.
Mechanism of Action
Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK) and ROS1-positive NSCLC. It works by inhibiting the activity of these kinases, which are involved in the growth and spread of cancer cells. By blocking these pathways, Lorlatinib can help to slow down or stop the progression of the cancer.
Indications
Lorlatinib is primarily indicated for:
- Treatment of ALK-positive metastatic NSCLC in patients who have progressed on or are intolerant to first- and second-generation ALK inhibitors such as crizotinib, ceritinib, or alectinib.
- Treatment of ROS1-positive metastatic NSCLC.
Administration
Lorlatinib is administered orally in the form of tablets. The recommended dosage is 100 mg once daily, with or without food. It is important for patients to take the medication at the same time each day to maintain consistent blood levels of the drug.
Dosage Adjustments
Dosage adjustments may be necessary based on:
- The presence of side effects.
- Drug interactions.
- Patient's liver function.
Side Effects
Like all medications, Lorlatinib can cause side effects. Some of the most common side effects include:
- Hypercholesterolemia (high cholesterol levels)
- Hypertriglyceridemia (high triglyceride levels)
- Peripheral neuropathy (numbness or tingling in the extremities)
- Cognitive effects (memory problems, mood changes)
- Edema (swelling)
- Weight gain
Serious Side Effects
In some cases, Lorlatinib can cause more serious side effects, such as:
- Interstitial lung disease/pneumonitis
- Hepatotoxicity (liver damage)
- Hyperglycemia (high blood sugar levels)
- Cardiac effects (heart rate changes, QT prolongation)
Patients experiencing serious side effects should seek medical attention immediately.
Clinical Considerations
Drug Interactions
Lorlatinib can interact with other medications, which may affect its efficacy or increase the risk of side effects. Some notable interactions include:
- Strong CYP3A inhibitors (e.g., ketoconazole) can increase Lorlatinib levels.
- Strong CYP3A inducers (e.g., rifampin) can decrease Lorlatinib levels.
- Medications that prolong the QT interval should be used with caution.
Monitoring
Patients on Lorlatinib should be regularly monitored for:
- Lipid levels (cholesterol and triglycerides)
- Liver function tests
- Blood glucose levels
- Neurological and cognitive function
- Cardiac function (ECG monitoring for QT prolongation)
Special Populations
- Pregnancy and Lactation: Lorlatinib can cause harm to a developing fetus and is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least 6 months after the last dose. It is also not recommended for use during breastfeeding.
- Pediatric Use: The safety and efficacy of Lorlatinib in pediatric patients have not been established.
- Geriatric Use: No overall differences in safety or effectiveness were observed between elderly and younger patients, but greater sensitivity in some older individuals cannot be ruled out.
The third-generation anaplastic lymphoma tyrosine kinase inhibitor (ALK-TKI) lorlatinib has a unique side effect profile that includes hypercholesteremia and hypertriglyceridemia in>80% of lung cancer patients.